Source comparison
Tesamorelin Before and After Timeline: What Imaging Shows vs What You See
Clinical imaging (CT or DEXА) detects visceral fat changes 6–10 weeks before those changes become visible externally. A subject with 150cm² of visceral adipose tissue at baseline might show 135cm² at week 8 (10% reduction). Statistically significant but not mi
This comparison does not assign a generated winner or score.
- Clinical imaging (CT or DEXА) detects visceral fat changes 6–10 weeks before those changes become visible externally. A subject with 150cm² of visceral adipose tissue at baseline might show 135cm² at week 8 (10% reduction). Statistically significant but not mirror-apparent because subcutaneous fat remains unchanged. By week 16, visceral area may drop to 120cm² (20% reduction), and waist circumference finally decreases noticeably as the abdominal cavity volume contracts.
- The lag exists because visceral fat sits behind the abdominal wall musculature. Losing 2cm of depth around the liver and intestines doesn't translate to 2cm of waist measurement. It translates to approximately 0.6–0.8cm due to the three-dimensional distribution of fat loss. This is why tesamorelin trials use CT imaging as the primary endpoint rather than waist circumference or scale weight. Real Peptides emphasizes this distinction in every protocol consultation: if your success metric is visual transformation within eight weeks, tesamorelin isn't the compound for that goal.
- A realistic before-and-after expectation at six months: 10–15% reduction in waist circumference (measured at the umbilicus), 15–20% reduction in visceral fat volume on imaging, 2–4kg scale weight reduction, and improved fasting glucose or lipid panels. The cardiovascular and metabolic benefits precede the cosmetic ones. Some subjects see HbA1c drop from 6.2% to 5.7% before their belt size changes.